



Proteomics International

LABORATORIES LTD

ASX Release
30 October 2023

ASX code: PIQ

Investor Presentation

Proteomics International Laboratories Ltd (Proteomics International; the Company; ASX: PIQ) is pleased to release a copy of its latest investor presentation for a non-deal roadshow to institutional investors.

Authorised by Dr Richard Lipscombe (Managing Director) and Mr Neville Gardiner (Non-Executive Chairman) on behalf of the Board of PIQ.

ENDS

About Proteomics International Laboratories (PILL) (www.proteomicsinternational.com)

Proteomics International (Perth, Western Australia) is a wholly owned subsidiary and trading name of PILL (ASX: PIQ), a medical technology company at the forefront of predictive diagnostics and bio-analytical services. The Company specialises in the area of proteomics – the industrial scale study of the structure and function of proteins. Proteomics International's mission is to improve the quality of lives by the creation and application of innovative tools that enable the improved treatment of disease.

For further information please contact:

Dr Richard Lipscombe
Managing Director
Proteomics International Laboratories Ltd
T: +61 8 9389 1992
E: enquiries@proteomicsinternational.com

Dirk van Dissel
Investor Relations & Corporate Advisor
Candour Advisory
T: +61 408 326 367
E: dirk@candouradvisory.com.au

Kyle Moss
Corporate Advisor
Euroz Hartleys
T: +61 8 9488 1400
E: kmoss@eurozhartleys.com

Proteomics International Laboratories Ltd

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: enquiries@proteomicsinternational.com | W: www.proteomicsinternational.com



Proteomics International

LABORATORIES LTD

Investor Presentation

30 October 2023

Non-deal Roadshow

Dr. Richard Lipscombe

Managing Director

This Presentation is provided by Proteomics International Laboratories Ltd (Proteomics International, Proteomics, the Company, ASX: PIQ).

You should not rely upon anything in this presentation and/or any information obtained from the Company, its Directors or their associates in deciding whether or not to seek to purchase the shares of the Company. This is not an offer to subscribe for securities in the Company.

The Presentation may contain quantitative statements of anticipated future performance such as projections, forecasts, calculations, forward-looking statements or estimates all of which are based on certain assumptions (Forward Looking Statements). The Forward Looking Statements may involve subjective judgements and are based on a large number of assumptions and are subject to significant uncertainties and contingencies, many of which are outside the control of the Company and may not prove to be correct.

No representation or warranty is made that any Forward Looking Statements will be achieved, or occur, or that the assumptions upon which they are based are reasonable or the calculations from which they have been derived are correct. Actual future events may vary significantly from the Forward Looking Statements. Each Recipient should undertake their own independent review of the Forward Looking Statements, including the assumptions on which they are based and the financial calculations from which they are derived.

Proteomics International Laboratories Ltd



A medical technology company at the forefront of precision medicine and predictive diagnostics

Three key focus tests driven by a proprietary platform technology:

Promarker**D**

Diabetic Kidney Disease

COMMERCIALISATION

- Proven predictive test for early detection of diabetic kidney disease (DKD)
- Being commercialised & launched in the US by Sonic Healthcare USA
- US\$390 indicative test price & PIQ receives royalty for each test sold

Promarker**Endo**

Endometriosis

DEVELOPMENT

- Test in development to diagnose Endometriosis
- Affects 1 in 9 women and costs Australia alone over AU\$10 billion a year
- Prototype test identified up to 90% of patients with the disease

Promarker**Eso**

Esophageal Cancer

DEVELOPMENT

- Test in development to diagnose Esophageal Cancer
- 1 in 20 cancer deaths worldwide due to oesophageal cancer
- Prototype test identified up to 90% of patients with the disease

Corporate Overview

Corporate Snapshot

ASX code	PIQ
Market Capitalisation	A\$110m
Cash (30 Sept '23 + ~\$1.8m R&D tax incentive due Q4 CY23)	\$4.9m

Share Price	A\$0.90
Shares on issue (+1.4m options)	122m

Revenue & other income – FY23	A\$3.3m
Average Quarterly cash burn – FY23	A\$1.55m

Volume

Price (\$)




Financial and Corporate

- Top 40 Shareholders hold 49%
- Directors are highly aligned with shareholders holding 18%
- Multiple institutional & family office shareholders on the register
- State-of-the-art laboratories
 - Accredited (ISO 17025 and ISO 13485) cutting-edge facility
 - Specialist proteomics technology platform
 - Analytical services – pharmacokinetic (PK) testing & biosimilars
 - Headquartered on QEII Medical Campus, Perth, WA
- Revenue generating
 - Bioanalytical service business helps offset cash burn
 - Current revenue does not include any major sales of PromarkerD

Promarker – Platform Technology



Promarker™ is a platform technology that can identify unique protein biomarkers ‘fingerprints’



The platform identifies and links the unique protein biomarkers to specific diseases, enabling Proteomics International to create novel diagnostic tests

Promarker D

PROACTIVELY CHANGING RENAL HEALTHCARE

A simple blood test for predicting diabetic kidney disease



Problem and Solution – Diabetic Kidney Disease



The Problem

- **537 million adults** with diabetes globally
- **1-in-3** with diabetes have chronic kidney disease
- **Kidney disease is a silent killer** - kidney function can **fall below 15-20% with no symptoms**
- Damage to kidneys is **irreversible**, therefore **early detection** is paramount
- Diabetic kidney disease leads to renal failure which requires **dialysis (US\$72,000 p.a.) or kidney transplant**
- Total cost of diabetic kidney disease = **US\$130 Bn** per year in USA alone




Roadblock



Solution

Current standard-of-care diagnostics

- Existing tests (known as eGFR and ACR) can only detect chronic kidney disease once it is already present
- Current standard-of-care tests cannot **predict** the onset of diabetic kidney disease
- **If unchecked, patients ultimately require dialysis and/or a kidney transplant**



Diseased Kidney


Promarker D

- PromarkerD can **predict** the onset of disease **before** clinical symptoms appear (up to four years prior)
- **Doctors can then prescribe an early therapeutic treatment to slow or stop the onset of disease**
- Kidneys remain healthier for longer, **saving healthcare systems billions of dollars** and **improving quality of life** for patients



Healthy Kidney

PromarkerD – Simple Integration & Use



Sample is drawn at clinic or pathology laboratory

Laboratory uses a standard technology platform

Advanced rapid immunoassay measures three plasma proteins -

combined with three simple clinical factors (age, cholesterol, eGFR)

CE Mark registered

Manufactured to ISO 13485 standard in Europe

Cloud based algorithm, the “PromarkerD Hub” calculates the patient’s kidney disease risk score

Employs a traffic light system for optimal performance, classifies patients as:

- low risk
- moderate risk
- high risk

Clinician delivers results to patient

Depending on results, intervention may include:

- change of lifestyle; and/or
- therapeutic drugs
 - SGLT2-inhibitor
 - GLP-1 agonist

PromarkerD in the Clinic



ASX: PIQ



Peer Reviewed

PromarkerD tested on **over 5,000 patients** in 4-year clinical studies

10+ Peer Reviewed Publications


World leading results: **Janssen**

- Global clinical study 3,568 participants from completed CANVAS clinical trial
- PromarkerD predicted 'incident DKD' high-risk patients **13.5 times more likely** than low-risk to develop DKD ($P = 1.3 \times 10^{-104}$)

[J. Clin. Med. (2020)]

- PromarkerD **high-risk patients show greatest benefit** from early use of SGLT2-inhibitor

[J. Clin. Med. (2023)]



Physician Support

Survey of 400 Endocrinologists & Primary Care Physicians (US based)

- **96% of physicians** were likely to use PromarkerD test scores for clinical decision-making
- PromarkerD consistently ranked as **one of the top 2 factors** driving physician decision-making:


- monitoring frequency
- use of anti-inflammatories
- prescribing SGLT2s
- ACE inhibitor dosing

[AMCP Nexus (2021)]



Outperforms Standard of Care

- 857 community based patients tested for existing DKD at baseline: 497 had normal kidney function
- 9% of patients developed DKD within 4 years:
 - PromarkerD accurately predicted 84% (N=38)
 - All were missed by Standard of care tests [ASN (2021)]



PromarkerD compared to standard of care tests (eGFR and ACR) for predicting DKD


PromarkerD Patented in all Major Markets

Diabetic Kidney Disease is becoming one of the largest burdens on healthcare systems globally

Patent family & Trademark covers 72% of world's diabetics¹

Country	Patent/Application No	Patent Status	No. Diabetics ¹
Australia	2011305050	Granted	1,491,800
Brazil	BR112013006740	Granted	15,733,600
Canada	2811654	Granted	2,974,000
China	ZL201180053583.9	Granted	140,869,600
Europe ^{2,3}	3151012	Granted	61,425,100
Hong Kong	18115912.3	Granted	686,000
India	3012/DELNP/2013	Granted	74,194,700
Indonesia	W00 2013 01585	Granted	19,465,100
Japan	2013-528474	Granted	11,005,000
Russia	2596486	Granted	7,392,100
Singapore	188527	Granted	711,800
USA ^{2,4}	US 9,146,243	Granted	32,215,300
			~368 million Total

1. International Diabetes Federation (IDF) Atlas 10th Edition 2021 [Age group 20-79 years]
2. Australia, Europe, HK, USA patent family also covers testing for any form of kidney disease (Extra efficacy studies required)
3. Covers France, Germany, Italy, Spain, Turkey and the United Kingdom
4. USA patent further extended to cover method for identifying drugs for abnormal kidney function using one of the PromarkerD biomarkers (CD5L)



Market assumptions

- Test is performed **once per year per patient** on average
- Standard industry **royalty rates range from 5-15%**

United States: Commercialisation in Progress

Sonic Healthcare USA has the exclusive licence to commercialise PromarkerD in the world's largest healthcare market



Over 7,000 Employees
Over 300 Sales reps
Over 400 pathologists
Services over 20 million patients



Marketing, Sample collection, Reporting



**PromarkerD Diabetic
Kidney Disease Risk
Assessment**

Early detection can significantly help prevent serious kidney damage.

CLIA Certified Laboratories

Sonic is the third Largest
laboratory medicine
company in the US



Test listed on Sonic website
& commercial launch
expected in Q1 CY24



Sonic has labs spanning from
Hawaii to Boston



Reimbursement Underway

Proteomics International has been working with its partner Sonic Healthcare USA on reimbursement in the US

CMS is the federal agency in the United States that administers Medicare and Medicaid

Medicare and Medicaid collectively responsible for 42% of healthcare spending in the US

CMS has assigned a payment rate of US\$390.75 for PromarkerD

CMS is responsible for providing healthcare coverage to more than 100m Americans

US Reimbursement Timeline

Unique CPT Proprietary Laboratory Analysis (PLA) code approved

Centers for Medicare and Medicaid Services (CMS) posts updated code list PLA code (0385U) for PromarkerD effective

American Clinical Lab Association engaged by SHUSA to consider crosswalk or gapfill pricing

CMS Clinical Lab Fee Schedule (CLFS) Annual Meeting to consider pricing

CMS proposed pricing of US\$390.75 for PromarkerD

CMS pricing effective for PromarkerD



Jan 2023



Apr 2023



May 2023



Jun 2023



Oct 2023



Jan 2024

Target Markets:



ASX: PIQ



United Kingdom

4.8m T2 diabetics

- **Licence with Apacor Ltd** for immunoassay test
- Test registered with Medicines & Healthcare products Regulatory Agency
- *National Institute for Health & Care Excellence (NICE) Medtech Innovation Briefing "NICE Advice" published*

Next Steps

- Engagement with the NHS Supply Chain Tender
- PromarkerD inclusion in the NICE guidelines
- MIB are looked at by the broader healthcare industry and allow for positive engagement with private healthcare providers



Puerto Rico & Dom Republic

1.3m T2 diabetics

- **Licence with Omics Global Solutions** for immunoassay (Innovatio ND2) in Puerto Rico & Dominican Republic
- Test registered with Ministry of Health
- *First sales commenced*

Next Steps

- Securing public reimbursement
- Expanding uptake of the test through engagement with primary care physicians
- Exploring additional sales to neighbouring territories



Israel

0.6m T2 diabetics

- **Licence with Zotal Ltd** for immunoassay test
- Product registration on-hold pending regulatory approval and first sales globally

Next Steps

- Engaged with Zotal to initiate product registration and promote KOL awareness



Rest of World

330m+ T2 diabetics

- Detailed market assessments completed

Next Steps

- Actively targeting potential partners in key jurisdictions


Pipeline of Precision Diagnostics

Platform technology drives deep pipeline of novel diagnostic tests

Further global potential in new markets

- Promarker™ platform develops novel intellectual property
- Targeting new diagnostic tests in areas of significant unmet need
- Enormous markets and revenue potential

DIAGNOSTICS RESEARCH AND DEVELOPMENT – THE PROMARKER™ PIPELINE



Dx Pipeline: Endometriosis & Oesophageal Cancer



ASX: PIQ

Proteomics International has two potential world-first blood tests in late-stage development

Impact of Endometriosis

- Endometriosis is a common and painful disease where uterus tissue grows into other organs
- Currently **diagnosis takes an average of 7.5 years** and requires invasive surgery (laparoscopy)
- **Affects 1 in 9 women** and **costs Australia over AU\$10 billion a year** – global opportunity significantly higher

Promarker™ for Endometriosis

- Prototype test identified up to **90%** of patients with the disease (World Endometriosis Conference, May '23)
- Collaboration with Royal Women's Hospital & University of Melbourne analysed 901 patients
- Biomarkers identified via the Promarker™ platform offer a **potential world-first blood test for endometriosis**
- Next steps: confirm clinical performance and clinical utility in additional cohorts



www.endometriosisaustralia.org/
www.clinicalomics.com



Impact of Oesophageal Cancer

- **1 in 20 cancer deaths worldwide** due to oesophageal cancer - **5 year survival rate < 20%**
- Currently diagnosis requires a specialist endoscopy procedure; **treating the disease cost \$2.9bn in USA in 2018**
- Test targets oesophageal adenocarcinoma and Barrett's esophagus (pre-malignant) which affects 1-2% of adults and can **arise from chronic acid reflux**

Promarker™ for Oesophageal Cancer and Barrett's esophagus


- Prototype test identified 90% of people with & without the disease (World Congress Esophageal Diseases, Sept '23)
- Collaboration with QIMR Berghofer Medical Research Institute analysed 302 samples;
- Results indicate a **potential world-first blood test to screen for oesophageal cancer**
- Next steps: confirm clinical performance and clinical utility in additional cohorts

Timeline & Milestones




ASX: PIQ

FY23 Achievements



FY24 Targets & Milestones



Value Inflection Points

Exceptional Global Opportunity







- Disruptive, cutting-edge technology & proven in-house diagnostics platform
- PromarkerD test de-risked, patented, revenue ready
- Test rolling-out in easy-to-use, scalable, low cost format with high margins
- Whole of market appeal: pharma, clinical pathology labs, diagnostic platform developers, diabetes service providers, physicians and patients
- Deep pipeline of potential globally significant tests in development
- Vibrant corporate activity in the precision medicine, diagnostics and CRO (clinical trials) sectors

Share Price Catalysts throughout FY24

Milestone	Qtr	Dec	Mar	Jun	Impact
PromarkerD					
First Sales in USA					Initiate pathway to significant revenues
CMS Reimbursement Pricing Set					Supports broad adoption of test
Regulatory Submissions, Approvals & Reimbursement RoW					Build user confidence in product & assist in global roll-out
Licensing Deals in RoW					Drive global uptake and future revenue
Promarker™					
Endometriosis Dx – update					New first-in-class diagnostic test
Oesophageal Cancer Dx - update					New first-in-class diagnostic test
Diagnostics Pipeline Updates					New IP (validation & proof of concept results)
Analytical Services					
New Contracts					Engages potential future partners & enhances revenue profile

Peer Comparison



		Stock Code	Company Focus	Market Capitalisation	Share Price	FY23 Revenue	FY23 Net Profit/Loss
	Proteomics International Laboratories	PIQ.ASX	Predictive blood test measuring novel protein biomarkers for DKD; simple, cost effective, commercial ready. Pipeline of novel diagnostic tests in development for chronic diseases.	A\$110m	A\$0.90	A\$0.7m	(-A\$6.2m)
	Innoviq Ltd	IIQ.ASX	Early stage in-licensed IP for various cancer diagnostics.	A\$55m	A\$0.60	A\$0.4m	(-A\$9.2m)
	Lucid Diagnostics Inc	LUCD.US	Cancer prevention medical diagnostics company with a DNA test (via LDT) for oesophageal cancer.	A\$85m	USD\$1.29	A\$0.4m 31/12/22	(-A\$88m) 31/12/22
	Renalytix AI	RENX.LSE RNLX.US	DKD test based on AI and predictive blood-based biomarkers, genetic factors and electronic health records. Expensive (US\$950 p/test), non-mass market.	A\$75m	GBP£0.40	A\$5.4m	(-A\$72m)
	Rhythm Biosciences	RHY.ASX	Pre-commercialisation proteomics derived diagnostic test for colon cancer licensed from CSIRO.	A\$40m	A\$0.18	Nil	(-A\$8.2m)
	Clarity Pharmaceuticals	CU6.ASX	Clinical stage radiopharmaceutical company focused on the diagnosis & treatment of serious disease.	A\$274m	A\$1.05	Nil	(-A\$24m)

Data sourced from ASX, Iress and Company Annual Reports as of 27th October 2023, USD/AUD 1.57, GBP/AUD 1.91


Dr Richard Lipscombe

Managing Director

T: +61 8 9389 1992

E: enquiries@proteomicsinternational.com

www.proteomicsinternational.com



Proteomics International

LABORATORIES LTD

Dirk van Dissel

Investor Relations & Corporate Advisor

Candour Advisory

T: +61 408 326 367

E: dirk@candouradvisory.com.au

Kyle Moss

Corporate Advisor

Euroz Hartleys

T: +61 9488 1400

E: kmoss@eurozhartleys.com



Board of Directors



Neville Gardiner BBus (Accounting and Business Law) (Curtin), Non-Executive Chair

Seasoned finance professional with over 30 years' experience providing corporate advice to Boards of public and private companies. He was Co-Founder and MD of Torridon Partners, an independent corporate advisory firm, which was acquired by Deloitte in 2016, where he became Partner in their M&A Advisory team.



Dr Richard Lipscombe PhD (London), MA (Oxon), Co-Founder & Managing Director

Led the Company from foundation through listing in 2015 to today. 30 years biotechnology experience in R&D and product commercialisation in academic and commercial entities. Technical expertise in chemistry, immunology, biomarker discovery & clinical proteomics.



Roger Moore R (Denmark), BPharm (U.Syd), Non-Executive Director

International pharmaceutical industry experience spanning 40 years, including almost 30 years as President of Novo Nordisk Japan. From 2000, he was appointed Novo Nordisk's Senior Vice President, Japan & Oceania Region. He has also served as a member of the Senior Management Board, Novo Nordisk A/S.



Paul House GAICD, BCommerce (UWA), Non-Executive Director

Over 25 years with multi-national corporations, CEO of Imdex (ASX:IMD), prior role as MD of SGS India for 8 years. Previously held CFO and COO roles, and was Senior Manager at a leading global management consultancy firm.



Dr Robyn Elliott PhD Inorganic Chemistry (Monash), BSc(Hons) Chemistry (Monash), Non-Executive Director

Proven track record in product development, clinical trials, regulatory affairs, audits, quality management, project management and operational strategy. Dr Elliott is Executive Director, Strategic Fractionation Program Delivery at CSL Behring, a subsidiary of CSL Limited. She is also a non-executive director of PolyNovo Limited (ASX:PNV).

PromarkerD: World Class Advisory Board



Proteomics International is supported by an international, highly acclaimed advisory board

Professor Tim Davis MedSc, MB, W.Aust., DPhil Oxf.,
FRACP, MRCP (UK) – *Australia*

Consultant physician and endocrinologist, Fremantle Hospital,
Professor of Medicine, University of Western Australia; WA Health
Department's Diabetes & Endocrinology Clinical Network Co-lead



Dr Ele Ferrannini MD – *Italy*

Professor of medicine, The University of Pisa
Adjunct Clinical Professor of Medicine, University of Texas
Health Science Center: Senior research associate,
National Research Council's Institute of Clinical Physiology



Ms Davida F. Kruger MSN, APN-BC, BC-ADM
– *United States*

Certified Nurse Practitioner, Henry Ford Health
Past Chair of the American Diabetes Association's (ADA)
Research Foundation; ADA Educator of the Year (2017)



Dr Joshua Neumiller PharmD, CDCES, FASCP, FADCES
– *United States*

Professor of Pharmacotherapy, Washington State University
Recipient of Albert B. Prescott Pharmacy Leadership Award (2016)
ADCES Diabetes Care & Education Specialist of the Year (2021)



Associate Professor Michael Shanik MD, FACP, FACE
– *United States*

Managing partner at Endocrine Associates of Long Island, PC
Clinical Associate Professor, Stony Brook University Hospital,
New York



Dr Neil Skolnik MD – *United States*

Professor of Family and Community Medicine,
Sidney Kimmel Medical College, Thomas Jefferson University
Associate Director, Family Medicine Residency Program
Jefferson Health



Professor Merlin Thomas MBChB, PhD, FRACP,
FAAHMS – *Australia*

Nephrologist, scientist and program leader, the Department of
Diabetes, Monash University
Founder and Chief Scientific Officer, RAGE Biotech Ltd



Dr Alexander Turchin MD, MS – *United States*

Director of quality for the division of endocrinology,
Brigham and Women's Hospital, Boston
Associate Professor of Medicine, Harvard Medical School
Fellow of the American College of Medical Informatics




Ms Hope Warshaw MMSc, RD, CDCES, BC-ADM,
FADCES – *United States*

Registered Dietician, Certified Diabetes Care and Education Specialist
President of the ADCES 2016 & Chair of the Academy's Foundation
2022-2023



PromarkerD – Results & Intervention

How PromarkerD results are delivered



Risk Score	Intervention	Testing Regimen
Low Risk	<ul style="list-style-type: none">Standard diabetes management	Test Annually
Moderate Risk	<ul style="list-style-type: none">More frequent monitoringOptimisation of lifestyleReview of glycemic targets and managementReview non-glycemic risk factorsAvoidance of potentially nephrotoxic drugs	Test every 6 months
High Risk	<ul style="list-style-type: none">Very close monitoringIntensive management strategies based on those for 'Moderate risk' aboveUtilisation of therapeutic drugs	Test every 3 months

*as defined by incident diabetic kidney disease (eGFR <60ml/min/1.73m²) in the next four years. Note: if eGFR level at the time of the test is already <60ml/min/1.73m², then the risk of a further decline in kidney function is defined as an eGFR decline >30% in the next four years



New Treatments to Slow DKD

US\$7bn of sales in 2020 from the gliflozin class of type 2 diabetes drugs (SGLT2-inhibitors)

PromarkerD has the potential to become a new standard of care and change clinical practice





Janssen collaboration assessed effect of SGLT2-inhibitor (gliflozin) vs placebo on PromarkerD risk scores

- **Aim:** Do 'at-risk' patients continue to decline, stabilize or recover?
- **Method:** Retrospective analysis of 2,008 patients from the CANVAS 4 year clinical trial:
- **Results:** Patients predicted at baseline by PromarkerD to be **high-risk** for developing DKD:
 - Treated with SGLT2i had **significantly lower scores** at Year 3 (Δ score: -5.6%; $p < 0.001$)
 - Patients on **placebo remained high** (Δ score: 4.5%; $p = 0.035$) (Time*TRT $p = 0.002$)
- **Conclusion:** SGLT2-inhibitors offer a potential treatment that can improve PromarkerD renal risk profile

J. Clin. Med. 2023, 12, 3247. <https://doi.org/10.3390/jcm12093247>

Article

Canagliflozin Attenuates PromarkerD Diabetic Kidney Disease Risk Prediction Scores

Kirsten E. Peters ¹, Scott D. Bringans ¹, Ronan S. O'Neill ¹, Tasha S. C. Lumbantobing ¹, James K. C. Lui ¹, Timothy M. E. Davis ^{2,*}, Michael K. Hansen ³ and Richard J. Lipscombe ¹


¹ Proteomics International, QEII Medical Centre, 6 Verdun Street, Nedlands, WA 6009, Australia

² Medical School, The University of Western Australia, Fremantle Hospital, Fremantle, WA 6959, Australia

³ Janssen Research and Development, LLC, Spring House, PA 19477, USA

* Correspondence: tim.davis@uwa.edu.au; Tel.: +61-8-9431-3229; Fax: +61-8-9431-2977

(This article belongs to the Special Issue [Editorial Board Member's Collection Series: Chronic Kidney Disease in Diabetes](#))



PromarkerD: Key Publications



PromarkerD Demonstrates Benefit of Early Treatment with SGLT2-inhibitors	Peters KE, et al. Canagliflozin Attenuates PromarkerD Diabetic Kidney Disease Risk Prediction Score. J Clinical Medicine. 2023 .
Clinical Utility	Fusfeld L, et al. Evaluation of the clinical utility of the PromarkerD in-vitro test in predicting diabetic kidney disease and rapid renal decline through a conjoint analysis. PLOS ONE. 2022 .
PromarkerD vs Standard of Care	Peters KE, et al. A Comparison of PromarkerD to Standard of Care Tests for Predicting Renal Decline in Type 2 Diabetes. Poster presented at ASN Kidney Week. 2021 .
Economic Health Benefit	Burchenal W, et al. Demonstrating the Economic Health Benefit of using the PromarkerD In Vitro Diagnostic Test in the Prediction of Diabetic Kidney Disease. Poster presented at the American Diabetes Association's 81st Scientific Sessions. 2021 .
Global Multi-centre Validation	Peters KE, et al. PromarkerD Predicts Renal Function Decline in Type 2 Diabetes in the Canagliflozin Cardiovascular Assessment Study (CANVAS). Journal of Clinical Medicine. 2020 .
Predicts Late-stage Renal Function Decline	Peters KE, et al. PromarkerD Predicts Late-Stage Renal Function Decline in Type 2 Diabetes in the Canagliflozin Cardiovascular Assessment Study (CANVAS). Poster presented at ADA. 2022 .
Prognostic Validation	Peters KE, et al. Validation of a Protein Biomarker Test for Predicting Renal Decline in Type 2 Diabetes: The Fremantle Diabetes Study Phase II. J Diab Comp. 2019 .
Prognostic Development	Peters KE, et al. Identification of Novel Circulating Biomarkers Predicting Rapid Decline in Renal Function in Type 2 Diabetes: The Fremantle Diabetes Study Phase II. Diabetes Care. 2017 .
Diagnostic Study	Bringans SD, et al. Comprehensive Mass Spectrometry Based Biomarker Discovery and Validation Platform as Applied to Diabetic Kidney Disease. EuPA Open Proteomics. 2017 .
Cross-platform Validation	Bringans SD, et al. The New and the Old: Platform Cross-Validation of Immunoaffinity MASS Spectrometry versus ELISA for PromarkerD, a Predictive Test for Diabetic Kidney Disease. Proteomes. 2020 .
Cross-over Validation	Bringans SD, et al. A Robust Multiplex Immunoaffinity Mass Spectrometry Assay (PromarkerD) for Clinical Prediction of Diabetic Kidney Disease. Clin Proteomics. 2020 .